<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592057</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-334-1775</org_study_id>
    <nct_id>NCT02592057</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India</brief_title>
  <official_title>A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of sofosbuvir (SOF)-based regimens
      administered as per the approved prescribing information in adults with chronic hepatitis C
      virus (HCV) infection treated in routine clinical practice in India.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions (ADRs) during treatment and up to 4 weeks after discontinuation of a SOF-based regimen</measure>
    <time_frame>Up to Posttreatment Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantification (LLOQ) 12 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>SOF-based regimens</arm_group_label>
    <description>Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF</intervention_name>
    <description>SOF tablets administered orally once daily based on approved prescribing information</description>
    <arm_group_label>SOF-based regimens</arm_group_label>
    <other_name>Sovaldi ®</other_name>
    <other_name>GS-7977</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults residing in India aged ≥ 18 years, who are infected with HCV, and for whom the
        treating physicians in the participating clinics have prescribed a SOF-based regimen as
        per the approved prescribing information.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV-infected patients living in India

          -  Treatment with a SOF-based regimen as determined by the patient's treating physician
             per the approved prescribing information.

          -  Patients who provide written and signed informed consent prior to initiation of
             treatment where required.

        Exclusion Criteria:

          -  Concurrent participation in an HCV clinical trial (except trials not testing
             investigational medicinal products)

          -  Patients presenting a risk of not being able to be followed (eg, patients planning to
             move or leave the country in a foreseeable future)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand P. Chokkalingam, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Wienbar</last_name>
    <email>charles.wienbar@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nirmal Hospital Pvt. Ltd.</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rajiv Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midas Institute of Gastro-enterology</name>
      <address>
        <city>Ramdaspeth, Nagpur</city>
        <state>Maharashtra</state>
        <zip>440 010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shrikant Mukewar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 29, 2015</lastchanged_date>
  <firstreceived_date>October 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
